Tvardi Therapeutics
TVRD
79 hedge funds and large institutions have $4.56M invested in Tvardi Therapeutics in 2024 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 15 increasing their positions, 24 reducing their positions, and 34 closing their positions.
0.3% less ownership
Funds ownership: 1.2% → 0.9% (-0.3%)
19% less funds holding
Funds holding: 97 → 79 (-18)
38% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 24
53% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 34
79% less capital invested
Capital invested by funds: $21.7M → $4.56M (-$17.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$524K |
| 2 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$275K |
| 3 |
Jane Street
New York
|
+$249K |
| 4 |
Goldman Sachs
New York
|
+$224K |
| 5 |
Two Sigma Advisers
New York
|
+$134K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.77M |
| 2 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$1.41M |
| 3 |
State Street
Boston,
Massachusetts
|
-$545K |
| 4 |
AI
Acuitas Investments
Seattle,
Washington
|
-$466K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$364K |
TVRD Hedge Fund Activity: Q2 2024 in Review
79 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q2 2024, worth a combined $4.56M — down 79% from $21.7M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of TVRD and 16 opened new positions — a net loss of 18 holders — while 24 trimmed existing stakes and 15 added.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $524K. The largest seller was BlackRock, cutting an estimated $1.77M.
- 79 institutional investors held Tvardi Therapeutics (TVRD) as of Q2 2024, down from 97 in Q1 2024.
- Funds reported $4.56M of Tvardi Therapeutics stock for Q2 2024, down 79% quarter-over-quarter.
- 16 funds opened new Tvardi Therapeutics positions in Q2 2024 and 34 closed out, a net change of -18 holders.
- The largest Tvardi Therapeutics buyer in Q2 2024 was BNP Paribas Financial Markets, an estimated $524K added.
- The largest Tvardi Therapeutics seller in Q2 2024 was BlackRock, an estimated $1.77M sold.
Based on aggregated 13F filings for Q2 2024.